Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
Integrated Diagnostics debuts with $30 million funding: Start-up diagnostics developer debuts with the support of a $30 million "Series A" financing round, led by InterWest Partners. The Seattle firm is developing genomic and proteomic technologies to identify organ-specific proteins and enable the diagnosis and prognosis of a variety of diseases. Areas of focus include personalized and preventive diagnostics for cancer, diabetes and Alzheimer's disease. "Integrated Diagnostics' research enabling technologies will allow us to cut in half the standard development times for diagnostics," said company founder Leroy Hood. Launched Oct. 14, Integrated Diagnostics is an outgrowth of a public-private partnership between the nation of Luxembourg and several American research institutions, including the Institute for Systems Biology. Hood is the current president of ISB, inventor of the DNA sequencer, and previous founder of more than a dozen biotech firms, including Amgen and Applied Biosystems
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.